Skip to main navigation
Obsidian Therapeutics corporate site Obsidian Therapeutics corporate site
  • Home
  • Overview
  • News & Events
    • News Releases
    • Presentations
  • Stock Information
    • Stock Quote & Chart
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Management Team
  • SEC Filings
    • SEC Filings
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact Us

SEC Filing Details

Document Details

Form
S-8
Filing Date
Aug 3, 2026
Document Date
Aug 3, 2026
Form Description
Securities offered to employees pursuant to employee benefit plans
Filing Group
Registration Statements
Company
Obsidian Therapeutics
Issuer
OBSIDIAN THERAPEUTICS, INC.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
XML - XBRL INSTANCE DOCUMENT

Investor Contact


Contact

Caroline Code
VP, Corporate Development & Investor Relations
ir@obsidiantx.com

Subscribe to our Email Alerts


Obsidian Therapeutics logo
  • Home
  • About Us
  • Our Science
  • Our Lead Clinical Program
  • Investors & Media
  • Join Our Team
  • Contact
  • Privacy
  • Terms of Use

© 2026 Obsidian Therapeutics. All Rights Reserved.

Our programs, including OBX-115, and cytoDRIVE® Platform are investigational and have not been approved by the FDA or any other regulatory agency.

Search Investors